MapLight Therapeutics
Most recent annual filing: 2026-03-26
- ML-055 next-gen M1 corporate update2026ML-055 next-gen M1 corporate update, 2026, routine
- ML-009 PAM corporate update2027ML-009 PAM corporate update, 2027, routine
- ML-021 M4 antagonist corporate update2027ML-021 M4 antagonist corporate update, 2027, routine
- ML-007C-MA VISTA Ph2 topline2H 2027ML-007C-MA VISTA Ph2 topline, 2H 2027, thesis-defining
- ZEPHYR-2 Study 311 topline2028ZEPHYR-2 Study 311 topline, 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
zolmitriptan
ML-004 Small Molecule Target: 5-HT1B, 5-HT1D, 5-HT1B/1D Agonist
ML-009
Small Molecule Target: GPR52
- Undisclosed indication
ML-055
- Undisclosed indication
ML-021
Small Molecule Target: M4 muscarinic receptor
Technology platforms
MapLight Discovery Platform
Circuit-based CNS drug discovery platform combining optogenetics, single-cell transcriptomics, and STARmap spatial transcriptomics to identify neural circuits causally linked to CNS disease symptoms and discover druggable targets within those circuits for therapeutic modulation.
Biotech Distilled coverage (5)
- 2026-08-19 UPDATE: MapLight Therapeutics (MPLT) - Catalyst4 Bought the Deal 🔒 Paid
- 2026-08-14 UPDATE: MapLight Therapeutics (MPLT) - The Missing Endpoint Shows Up 🔒 Paid
- 2026-08-05 UPDATE: MapLight Therapeutics (MPLT) - Now We Know Who Bought It 🔒 Paid
- 2026-07-31 UPDATE: MapLight Therapeutics (MPLT) - Somebody Sold the Bounce 🔒 Paid
- 2026-07-28 MapLight Therapeutics (MPLT) — Scientific Deep Dive for ML-007C-MA, ML-004, and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.